Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$82.28 -4.2%	$61.28	$4.77 ▼ $92.91	$6.22B	0.59	695,938 shs	776,842 shs
GMAB Genmab A/S	$28.24 +0.9%	$23.70	$17.24 ▼ $28.75	$18.12B	0.93	1.45 million shs	1.08 million shs
SMMT Summit Therapeutics	$18.12 -4.3%	$25.37	$15.55 ▼ $36.91	$13.46B	-1.02	3.79 million shs	6.66 million shs
TEVA Teva Pharmaceutical Industries	$18.69 -1.1%	$17.35	$12.47 ▼ $22.80	$21.44B	0.72	11.98 million shs	11.22 million shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+2.21%	-4.59%	+21.91%	+1,317.00%	+632.68%
GMAB Genmab A/S	+0.61%	+1.63%	+20.08%	+27.05%	+4.05%
SMMT Summit Therapeutics	0.00%	-2.57%	-29.04%	-4.58%	-40.68%
TEVA Teva Pharmaceutical Industries	-5.31%	-2.06%	+5.82%	+11.86%	+2.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$82.28 -4.2%	$61.28	$4.77 ▼ $92.91	$6.22B	0.59	695,938 shs	776,842 shs
GMAB Genmab A/S	$28.24 +0.9%	$23.70	$17.24 ▼ $28.75	$18.12B	0.93	1.45 million shs	1.08 million shs
SMMT Summit Therapeutics	$18.12 -4.3%	$25.37	$15.55 ▼ $36.91	$13.46B	-1.02	3.79 million shs	6.66 million shs
TEVA Teva Pharmaceutical Industries	$18.69 -1.1%	$17.35	$12.47 ▼ $22.80	$21.44B	0.72	11.98 million shs	11.22 million shs

10 Best Stocks to Own: Fall 2025

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+2.21%	-4.59%	+21.91%	+1,317.00%	+632.68%
GMAB Genmab A/S	+0.61%	+1.63%	+20.08%	+27.05%	+4.05%
SMMT Summit Therapeutics	0.00%	-2.57%	-29.04%	-4.58%	-40.68%
TEVA Teva Pharmaceutical Industries	-5.31%	-2.06%	+5.82%	+11.86%	+2.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	3.11	Buy	$99.43	20.84% Upside
GMAB Genmab A/S	2.70	Moderate Buy	$39.25	38.99% Upside
SMMT Summit Therapeutics	2.65	Moderate Buy	$33.79	86.46% Upside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	32.23% Upside

Current Analyst Ratings Breakdown

Latest ABVX, TEVA, SMMT, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
9/12/2025	ABVX Abivax	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$71.00 ➝ $101.00
9/9/2025	ABVX Abivax	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$112.00
9/8/2025	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/8/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
9/3/2025	SMMT Summit Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$40.00
9/3/2025	SMMT Summit Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$40.00
9/3/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$40.00
9/2/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/27/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$44.00 ➝ $50.00
8/19/2025	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00

(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$0.69 per share	N/A
GMAB Genmab A/S	$3.26B	5.56	$1.54 per share	18.35	$8.04 per share	3.51
SMMT Summit Therapeutics	$700K	19,229.20	N/A	N/A	$0.53 per share	34.19
TEVA Teva Pharmaceutical Industries	$16.54B	1.30	$3.16 per share	5.92	$4.74 per share	3.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$190.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	$1.14B	$1.99	14.19	15.87	1.62	37.53%	21.03%	16.98%	11/6/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$1.01	N/A	N/A	N/A	N/A	-208.64%	-181.28%	10/29/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$0.16	N/A	7.11	1.16	-0.95%	46.10%	7.18%	11/5/2025 (Estimated)

Latest ABVX, TEVA, SMMT, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/8/2025	Q2 2025	ABVX Abivax	-$0.90	-$0.86	+$0.04	-$0.86	$1.35 million	N/A
8/11/2025	Q2 2025	SMMT Summit Therapeutics	-$0.10	-$0.76	-$0.66	-$0.76	N/A	N/A
8/7/2025	Q2 2025	GMAB Genmab A/S	$0.39	$0.54	+$0.15	$0.54	$5.77 billion	$925.00 million
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	$0.66	+$0.02	$0.24	$4.34 billion	$4.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	1.29	0.77	0.77
GMAB Genmab A/S	N/A	6.22	6.20
SMMT Summit Therapeutics	N/A	5.13	5.13
TEVA Teva Pharmaceutical Industries	2.45	1.06	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
GMAB Genmab A/S	7.07%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
GMAB Genmab A/S	1.54%
SMMT Summit Therapeutics	84.90%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	75.57 million	N/A	Not Optionable
GMAB Genmab A/S	2,682	641.59 million	631.71 million	Optionable
SMMT Summit Therapeutics	110	742.85 million	112.17 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

ABVX, TEVA, SMMT, and GMAB Headlines

Recent News About These Companies

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

1 hour ago | globenewswire.com

Teva Pharmaceutical Industries Limited (TEVA)’s Emrusolmin Gains FDA Fast Track for Multiple System Atrophy

September 16 at 9:32 AM | insidermonkey.com

Lingohr Asset Management GmbH Has $302,000 Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

September 16 at 5:48 AM | marketbeat.com

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $54.37 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

September 16 at 3:06 AM | marketbeat.com

Drugmaker Corcept must face Teva lawsuit over mifepristone 'monopoly' for rare disorder

September 15 at 12:14 PM | reuters.com

Intech Investment Management LLC Has $5.37 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

September 14 at 4:45 AM | marketbeat.com

Plato Investment Management Ltd Sells 24,495 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

September 14 at 4:28 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by Amundi

September 12, 2025 | marketbeat.com

Zimmer Partners LP Purchases New Position in Teva Pharmaceutical Industries Ltd. $TEVA

September 11, 2025 | marketbeat.com

Here’s Why Sound Shore Fund Added Teva Pharmaceutical Industries Limited (TEVA) in Q2

September 10, 2025 | insidermonkey.com

Axiom Investors LLC DE Makes New Investment in Teva Pharmaceutical Industries Ltd. $TEVA

September 10, 2025 | marketbeat.com

Clearline Capital LP Takes Position in Teva Pharmaceutical Industries Ltd. $TEVA

September 10, 2025 | marketbeat.com

Teva Pharmaceutical Industries Limited (TEVA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

September 9, 2025 | seekingalpha.com

Adage Capital Partners GP L.L.C. Cuts Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

September 9, 2025 | marketbeat.com

Zacks Research Issues Pessimistic Forecast for TEVA Earnings

September 9, 2025 | marketbeat.com

Zacks Research Has Pessimistic Outlook of TEVA Q3 Earnings

September 9, 2025 | americanbankingnews.com

Parsifal Capital Management LP Sells 169,814 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

September 8, 2025 | marketbeat.com

Graham Capital Management L.P. Cuts Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

September 8, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. $TEVA Shares Acquired by NWI Management LP

September 7, 2025 | marketbeat.com

Ion Asset Management Ltd. Acquires 2,383,500 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

September 7, 2025 | marketbeat.com

Canada Pension Plan Investment Board Has $2.32 Million Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

September 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX, TEVA, SMMT, and GMAB Company Descriptions

Abivax NASDAQ:ABVX

$82.28 -3.59 (-4.18%)

Closing price 04:00 PM Eastern

Extended Trading

$82.87 +0.59 (+0.72%)

As of 04:48 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Genmab A/S NASDAQ:GMAB

$28.24 +0.25 (+0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$28.24 0.00 (-0.02%)

As of 04:31 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Summit Therapeutics NASDAQ:SMMT

$18.12 -0.82 (-4.33%)

Closing price 04:00 PM Eastern

Extended Trading

$18.02 -0.10 (-0.52%)

As of 04:50 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$18.69 -0.20 (-1.06%)

Closing price 03:59 PM Eastern

Extended Trading

$18.71 +0.02 (+0.11%)

As of 04:46 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABVX, TEVA, SMMT, and GMAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABVX, TEVA, SMMT, and GMAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABVX, TEVA, SMMT, and GMAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX, TEVA, SMMT, and GMAB Company Descriptions

Abivax NASDAQ:ABVX

Genmab A/S NASDAQ:GMAB

Summit Therapeutics NASDAQ:SMMT

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABVX, TEVA, SMMT, and GMAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABVX, TEVA, SMMT, and GMAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABVX, TEVA, SMMT, and GMAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX, TEVA, SMMT, and GMAB Company Descriptions

Abivax NASDAQ:ABVX

Genmab A/S NASDAQ:GMAB

Summit Therapeutics NASDAQ:SMMT

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools